Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
261.43 K
Value Traded
240.94 K
Short % Float
0.29%
Days to Cover
1.0
+16.33%Week
+0.88%1 Month
-37.7%3 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
161.20 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
141.29 M
Float Shares
36.83 M
Insiders
75.07%
Institutions
0.33%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
VRXA Catalyst Timeline
Dated clinical, regulatory and corporate events for Veraxa Biotech AG
Catalyst Timeline
Dated clinical, regulatory & corporate events for Veraxa Biotech AG
25Total events
2Upcoming
3Tier-1 (high impact)
2025 to 2028Coverage
Upcoming catalysts 2
Event history 19
▲Preclinical PoCPreclinical
First in vivo proof-of-concept data for BiTAC-ADC platform showing tumor regression in xenograft breast cancer model
breast cancersource ↗
●Poster PresentationPresentation
Poster presentation of in vitro BiTAC-ADC data at 17th World ADC Congress
solid tumorssource ↗
▲Platform ValidationPreclinical
BiTAC-ADC platform concept validated by in vivo tumor regression data
solid tumorssource ↗
▲Preclinical PoCPreclinical
Initial positive results from AOC research collaboration
autoimmune and chronic immune diseasessource ↗
▲Milestone PaymentCorporate
VXA-222 achieves key technical milestone in OmniAb collaboration
solid tumorssource ↗
▲Development Candidate NominationVXA-222Preclinical
VXA-222 advances to next collaboration phase after successful discovery work
solid tumorssource ↗
▲FDA Feedback ReceivedFDA Meeting
Received Scientific Advice from Paul-Ehrlich-Institute on BiTAC-TCE development plan
▲Partnership / LicenseCorporate
AI-enabled drug discovery collaboration with Ardigen to support BiTAC pipeline
◆Pipeline PrioritizationCorporate
Pipeline prioritization: focus on BiTAC portfolio, monetize non-BiTAC assets
●Manufacturing MilestoneCMC / Inspection
Initiation of cell line development for lead BiTAC-TCE program with ATUM
cancersource ↗
●Composition Patent FiledIP / Competition
First patent applications filed for BiTAC-TCE and BiTAC-ADC platforms
▲Patent GrantedIP / Competition
Previously granted patents covering auxiliary technology modules cleared opposition period
▲Oral PresentationPresentation
Initial data from lead BiTAC-TCE program presented at AACR 2026
cancersource ↗
▲Poster PresentationPresentation
Presented initial data on BiTAC-TCE candidate at AACR Annual Meeting 2026
cancersource ↗
▲Preclinical PoCPreclinical
Initial data on most advanced BiTAC-TCE program presented at AACR Annual Meeting 2026
solid tumorssource ↗
▲Partnership / LicenseCorporate
Alliance and joint discovery collaboration with OmniAb established
Past FDA Catalysts and PDUFA Decisions
How VRXA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 97%
Micro Cap(rank 653 of 673)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every VRXA program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Gruninger MarcDirector | Buy | 9,133 10,000 held | $1.00 | 10/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VRXA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in VRXA for Q2 2026. | ||||
VRXA Institutional Ownership Trends
VRXA Short Interest
Shares sold short, counted twice a month.
0.29%
Short % of Float
of tradable shares sold short
107.4K
Shares Sold Short
-54.3% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
421.0K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VRXA ranks across every disease it competes in
Competitive Position is a premium feature
See how VRXA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVRXA News
-VRXA
Oct 13, 2026▲ +5.3%on this news
VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress
VERAXA Biotech presented promising in vivo proof-of-concept data for its BiTAC-ADC technology at the World ADC Congress. The data revealed significant tumor regression in a breast cancer model with a single dose. The BiTAC-ADC platform shows potential to enhance safety and efficacy compared to conventional antibody-drug conjugates.
Read more →-VRXA
Oct 7, 2026▲ +11.1%on this news
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
VERAXA Biotech has announced its strategy to implement FDA-aligned New Approach Methodologies (NAMs) in its R&D programs, aiming to reduce animal testing and accelerate clinical development. The company is utilizing advanced technologies, including cell-based assays and organ-on-chip systems, to enhance the predictivity of human biological responses. Initial data from its BiTAC-TCE program indicates promising efficacy and safety profiles, positioning VERAXA favorably within the evolving regulatory landscape.
Read more →-VRXA
Sep 4, 2026▲ +15%on this news
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
VERAXA Biotech AG has appointed Raju Willener as its new Chief Financial Officer. With over 30 years of experience in financial leadership, Willener will enhance the company's capital strategy and support its oncology pipeline development. His previous roles include Director of Corporate Development at Exentis Group AG, where he led M&A initiatives. The appointment is seen as a pivotal move for VERAXA as it progresses in its growth phase.
Read more →-VRXA
Aug 24, 2026▼ -8.7%on this news· ran to -26% by day 3
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
VERAXA Biotech and Secarna Pharmaceuticals have announced positive results from their collaboration on antibody oligonucleotide conjugates (AOCs) aimed at treating autoimmune and chronic immune diseases. The initial studies indicate that the AOC candidate shows greater potency than traditional oligonucleotides. Both companies are optimistic about the potential of AOCs in precision medicine and are planning the next steps in their partnership.
Read more →-VRXA
Jul 29, 2026VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
VERAXA Biotech AG has announced an update on its patent portfolio, filing new applications for its innovative T cell engager and antibody-drug-conjugate platforms. With over 50 patents granted in 14 countries, the company aims to protect its technologies through at least 2047. CEO Christoph Antz emphasized the importance of intellectual property in advancing their novel cancer therapies.
Read more →-VRXA
Jul 27, 2026▲ +11.7%on this newsshared move
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
VERAXA Biotech AG has announced the advancement of its bispecific antibody drug conjugate program, VXA-222, following a key technical milestone in collaboration with OmniAb. The program aims to target two different antigens on solid tumors using a novel AND-gate logic. This partnership combines OmniAb's antibody discovery technologies with VERAXA's linker technology, paving the way for further development of promising cancer therapies.
Read more →-VRXA
Jul 24, 2026▲ +11.7%on this newsshared move
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
VERAXA Biotech AG held an Extraordinary General Meeting where shareholders approved all proposed resolutions with over 99.94% support. The approved amendments enhance the company's corporate and financing framework, allowing for strategic partnerships and growth initiatives. This reflects strong shareholder confidence in VERAXA's long-term strategy in developing innovative cancer therapeutics.
Read more →-VRXA
Jul 23, 2026▼ -9.3%on this newsshared move
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
VERAXA Biotech has appointed Christoph Erkel, Ph.D., as Chief Scientific Officer to lead the development of its BiTAC® technology platforms. Erkel, who has over 20 years of experience in antibody therapeutics, aims to enhance the company's pipeline and accelerate its clinical programs. He succeeds Rick Austin, who contributed significantly during his tenure.
Read more →-VRXA
Jul 20, 2026VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
VERAXA Biotech has received Scientific Advice from the Paul-Ehrlich-Institute regarding its BiTAC-TCE development plan. The feedback supports the biological rationale of the technology and provides clarity for future development. Initial data from the program indicates a promising safety profile and efficacy, suggesting a potential improvement over traditional therapies.
Read more →-VRXA
Jul 13, 2026VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
VERAXA Biotech has announced a collaboration with Ardigen to enhance its BiTAC pipeline using AI-driven drug discovery methods. This partnership aims to improve the selection of cancer target pairs for T cell engagers and antibody drug conjugates, potentially increasing success rates in drug development. The innovative approach may also widen the therapeutic window by minimizing toxicity.
Read more →-VRXA
Jul 10, 2026VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
VERAXA Biotech AG has appointed Carl von Halem as Interim Chief Financial Officer, succeeding Torsten Bürgermeister. Von Halem brings significant experience from his role at Xlife Sciences and is expected to aid in the company's expansion. VERAXA is also in the process of finalizing a permanent successor to support its growth strategy.
Read more →-VRXA
Jul 6, 2026▲ +7.4%on this news· ran to +49% by day 1
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
VERAXA Biotech AG has reported significant advancements in its pipeline and partnering strategy, particularly with its BiTAC technology. The company aims to prioritize its BiTAC portfolio, with plans to have its first BiTAC-TCE candidate ready by early 2028. Recent industry events have generated positive feedback and interest in their therapeutic programs, enhancing their position for potential partnerships.
Read more →-VRXA
Jul 2, 2026▲ +18.3%on this news· ran to +60% by day 3shared move
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
VERAXA Biotech has begun cell line development for its BiTAC-TCE program in collaboration with ATUM, utilizing Leap-In Transposase technology. This initiative aims to create stable clonal cell lines essential for the clinical development of their T-cell engager candidates. The company highlights the importance of this step following encouraging preclinical results presented at the AACR Annual Meeting.
Read more →-VRXA
Jun 24, 2026▼ -21%on this news
VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
VERAXA Biotech has expanded its R&D hub in Heidelberg, Germany, to support its growing drug development programs. This expansion allows for team growth and the installation of necessary laboratory equipment. The company focuses on innovative cancer therapies, particularly through its BiTAC strategy, which aims to improve treatment precision. The move reinforces its commitment to advancing its pipeline into clinical development.
Read more →-VRXA
Jun 18, 2026▼ -23.5%on this news· ran to -61% by day 3shared move
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
VERAXA Biotech has announced successful in vitro proof-of-concept data for its BiTAC-ADC technology platform, which aims to enhance precision in cancer treatment. The company will present this technology at the BIO International Convention, seeking partnerships to further develop its innovative cancer therapies. The platform is designed to minimize off-tumor toxicity while maximizing therapeutic effects.
Read more →-VRXA
Jun 10, 2026VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
VERAXA Biotech AG has completed its business combination with Voyager Acquisition Corp., becoming a publicly traded company on the Nasdaq under the ticker VRXA. The merger enhances VERAXA's financial position with $27.5 million in secured notes and a $50 million share purchase agreement. The company is focused on developing next-generation cancer therapies using its proprietary BiTAC platform, which targets solid tumors with precision.
Read more →-VRXA
May 28, 2026VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
VERAXA Biotech AG has announced a significant financial boost through a $27.5 million senior secured note and a $50 million share purchase agreement. These transactions are aimed at supporting the closing of its business combination with Voyager Acquisition Corp. and advancing its pipeline of next-generation cancer therapies. The company is also preparing for a NASDAQ listing, which is expected to enhance its market presence.
Read more →About Veraxa Biotech AG
BIOPHARMAWATCH ELITE PLUS
Trade the next VRXA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime